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Abstract
MUTATION OF THE VESICULAR MONOAMINE TRANSPORTER-1 GENE
ALTERS ITS PROTEIN PRODUCT

By Abena Watson-Siriboe, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Biology at Virginia Commonwealth University.
Virginia Commonwealth University, 2010
Major Director: Jennifer K. Stewart
Associate Professor and Graduate Director, Department of Biology
The vesicular monoamine transporter 1 (VMAT1) is essential for storage of monoamines,
such as epinephrine and serotonin, in secretory vesicles of neuroendocrine cells. Recently
the VMAT1 protein was detected in human and mouse brain, and mutations of the
VMAT1 gene at single DNA nucleotides (single nucleotide polymorphisms or SNPs) were
associated with schizophrenia. In this study, Chinese hamster ovarian cells were stably
transfected with either human VMAT1 DNA (GenBank: #NM_003053.1) or DNA with
the Thr4Pro SNP, which results in a threonine to proline change in amino acid number 4
of the VMAT1 protein. Western blot analysis revealed that cells with the SNP produced
immunoreactive human VMAT1 proteins of altered molecular size, suggesting that SNP
Thr4Pro modifies either folding or processing of the VMAT1 protein. This finding is the
first evidence for biochemical consequences of a mutation in the human VMAT1 gene.

Introduction

A Brief Review of Vesicular Monoamine Transporters
The Solute Carrier gene family (SLC) consists of proteins that exhibit transporter
function. Five SLC families are responsible for the transport of neurotransmitters, biogenic
amines, ammonium and choline (9). Vesicular neurotransmitter transporters play a role in
the proper function of neural processes by regulating the storage and release of classic
neurotransmitters such as norepinephrine, dopamine, and serotonin. (17) These
transporters act by sequestering neurotransmitters into subcellular compartments, such as
vesicles, resulting in a regulation of the transmitter signal as well as protection against the
cytotoxic effects of such compounds. Four types of vesicular neurotransmitter transporters
have been identified: monoamine (VMAT), acetylcholine (VAchT), glutamate (VGluT)
and GABA (VGAT) transporters (6). These transporters share several characteristics, but
the VMATs are of particular interest in this study.
The vesicular monoamine transporters (VMATs) are part of the SLC18 gene family
of vesicular amine transporters. Two isoforms have been identified, VMAT1 and VMAT2,
which share a 60% sequence identity (5). Vesicular monoamine transporters are
responsible for the sequestration of biogenic amines such as dopamine and norepinephrine
within neuronal and endocrine cells (1). The structure of these transporters is characterized
by twelve transmembrane domains resulting in a major 55 kDa molecule.(5). VMAT 1 has
several substrates including dopamine, serotonin, norepinephrine and epinephrine. VMAT
2 shares the same substrates but binds histamine with higher affinity (5).

A vacuolar ATPase not directly associated with the transporter is responsible for
producing a proton gradient across the vesicular membrane (5; 19). This proton gradient is
utilized by the VMAT’s antiporter activity, exchanging two protons for each monoamine
taken into the vesicle (19). Binding of the first proton to the transporter results in a
conformational change, exposing a high affinity binding site. Binding of the second proton
results in the transport of the monoamine into the vesicular space (24). During an action
potential, contents of the vesicle are discharged into the extracellular space by exocytosis
(9).
Although the VMATs share structural similarities, it was initially believed that they
were located in different anatomical locations. Vesicular monoamine transporter 2 was
initially identified in neurons of the brain and peripheral nerve endings, whereas; VMAT 1
is associated with the adrenal medulla and neuroendocrine cells (5). Karen Brennan of the
Stewart lab (VCU) detected VMAT1 within the mouse medulla/pons by reversetranscriptase polymerase chain reaction (RT-PCR). This novel finding is further
complemented by the detection of VMAT1 in human postmortem brain tissue by both
Western blots and real-time polymerase chain reaction (12). Highest levels of human
VMAT1 were identified in the substantia nigra, amygdala and hippocampus (13). The
novel discovery of VMAT1 in the human brain does not make the linkage of mutations in
the transporter’s gene to bipolar disorder and schizophrenia suprising.
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The Schizophrenia Conundrum
Schizophrenia is a multi-faceted neuropsychiatric disorder that affects 1% of the
global population (16). The disorder is characterized by deteriorations in behavior,
cognition and emotions (1). Symptoms of this disorder include: delusions, paranoid
presentation and impaired memory (20). No single factor has been linked to susceptibility
to developing the disorder. Combinations of environmental and genetic factors have been
thought to increase susceptibility. Factors such as maternal infection and nutritional
deficiency have been linked to susceptibility as well as increased paternal age and fetal
hypoxia (22). The most commonly supported factors are those that affect
neurodevelopment and neurotransmitter regulation.
The gene “Disrupted in Schizophrenia 1” (DISC1) has been linked to several
psychiatric disorders including bipolar disorder, autism and schizophrenia (23). DISC1 has
many protein partners and often acts as a precursor to several pathways. The protein is
highly expressed during development and is associated with several processes such as
synaptic plasticity, neural migration and acting as a cytoskeletal scaffold protein (3; 10).
The protein also has been identified at synapses. However, its role serves in the etiology of
schizophrenia is unknown.
The prevailing hypothesis for the etiology of schizophrenia focuses on dopamine,
which functions in motor activity, attention, stress and reward seeking behavior (14).
Dysregulation of dopamine, in a regionally specific manner, may be linked to symptoms of
schizophrenia such as psychosis. Upregulation of dopaminergic receptors has been
hypothesized to play a large role in the dysregulation of this neurotransmitter (11). Several
3

genes have been identified that play a role in dopamine dysregulation; however, these
genes are rare and fail to account for a majority of schizophrenia cases.
Recent studies also implicate dysregulation of serotonin and specific serotonin
receptors in schizophrenia. For example, the use of the drug iloperidone, an antagonist of
both dopamine and serotonin receptors (15), has been approved by the FDA for treatment
of schizophrenia.
Schizophrenia has a non-Mendelian mode of inheritance (8). Although multiple
susceptibility genes have been identified to have links to schizophrenia, these genes each
have a small effect on the susceptibility to the disorder (8). Alterations in genes such as
DISC1 result in a several fold increase in risk of developing schizophrenia, but no single
gene has been identified to definitively cause the disease upon mutation or deletion.

Linkage of VMAT1 to Schizophrenia
Chromosome 8 of the human genome is one of the best supported regions for
susceptibility for schizophrenia and bipolar disorders. Approximately 8.5% of the genes
contained in 8p are involved in cerebral development, plasticity and maintenance (21). Of
the many genes on chromosome 8, one is of particular interest, SLC18A1 or the human
VMAT1 gene.
Several single nucleotide polymorphisms have been identified in this gene.
Sequenced DNA from schizophrenic Caucasian post-mortem brain tissue revealed a
missense homozygous mutation in the SLC18A1. This single base mutation, A277C,
resulted in a single amino acid change in the protein sequence conferring a threonine to
4

proline change at amino acid residue 4. This phenomena was seen in 21.4% of the
schizophrenic group compared to 2.6% in the contol group (2). The first time VMAT1 was
associated with susceptibility to schizophrenia. This finding was supported by the
identification of the same SNP linked to schizophrenia in a subset of the Han Chinese
population (4). Furthermore, two other laboratories have reported associations of other
mutations of the VMAT-1 gene with either schizophrenia or bipolar disorder in
populations of European and Japanese descent (1; 18). Specific effects of these single
nucleotide polymorphisms on expression and biochemical properties of the human
VMAT1 protein are not known.
The goals of this study were: (1) To stably transfect a cell line with expression
vectors containing wild type human VMAT1 DNA or human VMAT1 DNA with the
A277C mutation, and (2) To investigate effects of the A277C mutation on VMAT1 protein
produced by the cells, specifically effects on immunoreactive protein observed on western
blots and on the protein’s transport activity. Investigation of biochemical consequences of
VMAT1 mutations linked to schizophrenia may give further insight into the etiology of
this complex disorder.
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Materials and Methods

Cloning VMAT1 from human brain and adrenal RNA
The initial procedure was to reverse transcribe human brain and adrenal VMAT1
RNA to VMAT1 cDNA and amplify with PCR to obtain sufficient quantities of the DNA
for cloning and transfection into cells. Human brain and adrenal RNA were obtained from
Stratagene (La Jolla, CA 540133, 540005). Three µg of each sample RNA were reverse
transcribed with the SuperscriptTM Preamplification System (Invitrogen, Carlsbad, CA).
Each reaction contained 2µl of the following 10X stock solutions: 0.5 µg oligo dT
primers, 25 mM MgCl2, 0.1M DTT and 10X PCR buffer containing 20mM Tris-HCl and
50 mM KCl. One µl of 10mM dNTP was added and enough DEPC water to result in a
final volume of 21 µl. Reactants were incubated for 5 min at 42° C prior to addition of 1
µl Superscript RT II (200 U/µl) to sample tubes. Reactants were incubated for an
additional 50 min at 42° C in a thermocycler. The reaction was terminated by incubating
tubes at 72° C for 15 min then held at 4° C until placement on ice. Residual RNA was
degraded using 2 U of RNase H (GibcoBRL) and incubated at 37° C for 20 min
Polymerase Chain Reaction (PCR)
Each PCR reaction contained 6 µl of RT product, 10 µl PCR buffer, 3 µl 50mM
MgCl2, 2 µl 10 mM dNTP mix, 0.5 µl Taq DNA Polymerase (5 U/µl), 70.5 µl DEPC
treated water, 8.0 µl primer mix (forward and reverse primers, 0.05 nmol/ul each). The
cDNA was amplified for 40 cycles for the target and 30 cycles for β-actin (15 sec at 94 °C,
15 sec at 56 °C and 30 sec at 72 °C). The reaction was held at 72 °C for 5 min , then at 4
6

°C until samples were stored at -20 °C. PCR for β-actin was performed as a control to
determine the efficacy of the RT-PCR reaction.

Primers
PCR primers for RT-PCR were created using the Primer 3 program
(http://frodo.wi.mit.edu/primer3/) and ordered from Invitrogen (Carlsbad, CA). Primers
were designed to span at least 100 bp past the beginning and end of the target sequences
(Table 1). PCR product was isolated by size by gel electrophoresis containing 1% agarose,
1X TAE buffer (Invitrogen Carlsbad, CA) and 0.5 µl of Ethidium Bromide (10mg/ml).
Electrophoresis was run for 0.5 hours at 90 V. Human VMAT1 band was expected at
1762 bp and human β-actin at 208 bp. Gels were visualized and photographed with the
BioDoc-It Imaging System (UVP, LLC Upland, CA). RT-PCR product was expected to
produce a band size of approximately 1762 bp upon analysis by gel electrophoresis

Table 1. Reverse Transcriptase Polymerase Chain Reaction Primers
Primer
Target
hVMAT1
β-actin

Forward Primer 5'-3'
AAGTGAGTTTCCTTCGTCTGG
GGCCACGGCTGCTTC

Reverse Primer 5'-3'
GTCCCAGGGAAAGAGGTGGT
GTTGGCGTACAGGTCTTTGC

Expected Size Fragment
(bp)
1762
208

As shown in Figures 1 and 2, RT-PCR of neither brain nor adrenal produced
product that could be isolated from the gel for cloning. Bands at the bottom of the gel
represent unused primers. β-actin controls for both adrenal (lane 6) and brain (lane 8)
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samples produced robust bands at 208 bp (Figure 1). DNA in lanes 3 and 5 appears to be
represent many amplified fragments, suggesting a problem with the primers chosen for the
RT reaction.

3,000 bp
2,000 bp
1,500 bp

hVMAT1

1,000 bp
700 bp
500 bp
300 bp
β-actin

100 bp
No
RT

AD

No
RT

BR

AD

No
RT

BR

No
RT

No
RNA

Figure 1. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). AD =
adrenal; BR = brain; No RT = reactions omitting the reverse transcriptase enzyme.
Expected positions of hVMAT1 and β-actin products are shown on the right. Unused
primers are at the bottom of No RT and No RNA lanes. The product is lane 7 may reflect
primer dimers.

When the reaction was repeated with additional RNA samples and with 40 cycles
of amplification the results did not improve. Figure. 2 demonstrates the best of these
results. A faint band of approximately 1700 bp was observed in the brain sample.
However, the yield for the reaction was too low for cloning purposes.
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3,000 bp
2,000 bp
1,500 bp

hVMAT1

1,000 bp
700 bp
500 bp
300 bp
100 bp
No
RNA

No
RT

AD

BR

No
RT

Figure 2. Reverse Transcriptase Polymerase Chain Reaction in Human Adrenal and
Brain samples. RT-PCR products from human brain and adrenal RNA are shown. AD=
human adrenal gland. BR= human brain No RT= no reverse transcriptase. The expected
position of hVMAT1 product is shown on the right. Bands at the bottom of all lanes may
reflect unused primers.

Due to the difficulty in obtaining human VMAT1 cDNA from RNA, the human
VMAT1 sequence was purchased from Origene (Rockville, MD) in the pCMV6-XL5
vector, which also contained the ampicillin resistance gene. In order to produce a stably
transfected mammalian cell line, the VMAT1 cDNA insert had to be transferred to a vector
containing both ampicillin and neomycin resistance as described below.
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Transfer of hVMAT1 from pCMV6-XL5 to pCMV6-Neo Vector
SLC18A1 (h-VMAT-1) in a pCMV6-XL5 vector was purchased from Origene
(Rockville, MD SC122643). The plasmid was amplified in E. coli DH5α and purified with
a midi-prep protocol by the Molecular Biology Core Laboratory (Virginia Commonwealth
University), yielding 100 µl of product containing 2.623 µg/µl of plasmid. One µg of
plasmid DNA was digested with Not I (Invitrogen Carlsbad, CA).

A portion of the

sample (1µl) was diluted to a concentration of 0.5 µg/µl in T10-E0.1 buffer (10mM
TrisHcl and 0.1mM EDTA, pH 8.0), and 1µg of vector containing the insert was digested
with Not I (Invitrogen Carlsbad, CA) according to manufacturer directions. Not I digestion
product was separated by gel electrophoresis on a gel containing 1% agarose, 1X TAE
buffer (Invitrogen) . A 5 µl aliquot of digestion product and a 1 kb ladder were loaded into
the gel and run at 90 V for approximately 0.5 hrs. Two resultant bands were identified, the
empty vector (approximately 5800 bp) and insert (approximately 2770 bp).
Upon imaging, the target bands were identified and excised from the gel. Excised band
weight ranged from 47-48 mg. Insert DNA was isolated from the excised band with the
QIAquick gel extraction kit (Qiagen Valencia, CA) by the manufacturer’s protocol and
dissolved in T10-E0.1 buffer. The resultant concentration was measured with the
NanoDrop (SID-10135606, Thermo Scientific).

DNA ligation and E. Coli transformation
Isolated insert was ligated into the pCMV6-Neo vector for the purpose of stable
transfection. The ligation reaction consisted of : 1 µl 10X ligation buffer, 1ul pCMV6-Neo
10

vector, 2 µl purified insert, 2 µl T4 ligase (New England Biolabs Beverly, MA) and
ultrapure water up to a final volume of 10µl. The ligation was allowed to react for one
hour at 37 ° C. Transformation of DH5α E. coli cells was performed with the heat shock
method (50 μl of E. Coli cell culture was combined with 10 μl of ligation mix and allowed
to incubate on ice for 20 min The mixture was then incubated at 37° C for 4 min, then
allowed to grow for 1.5 hours at 37° C while shaking. The resultant culture was transferred
to an agar plate containing 100 mg/L ampicillin). Cultures were incubated at 37° C
overnight.

Plasmid Midi Prep and Determination of Insert Orientation
Thirteen single colonies were selected and allowed to grow in LB broth containing
100 µg/ml ampicillin overnight at 37 °C, then transferred to 1.5 ml tubes and centrifuged at
16,0000 x G for 5 min The pellet was resuspended in 0.3 ml of STET Buffer (8% Sucrose,
5% Triton X-100, 50 mM EDTA, 50 mM Tris, pH 8.0) . Lysozyme (25 µl at 20 U/ µl)
was added, and tubes were placed in boiling water for 60 sec. Samples were then
centrifuged at 16,000 x G at room temperature and the pellet removed. Cold isopropanol
(300 µl) was added to precipitate the DNA. Samples were centrifuged at 16,000 x G at
room temperature and pellets were washed with 70% ethanol. Pellets were then allowed to
dry and resuspended in 20 µl T10-E0.1.
To determine insert orientation, a web based tool provided by New England
Biolabs (Ipswich, MA) was used to identify restriction sites within the h-VMAT-1
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sequence (http://tools.neb.com/NEBcutter2/index.phpp). Isolated DNA was digested with
Xmn1 (New England BioLabs Ipswich, MA). The plasmid was digested with 0.5 µl Xmn1
(20U/μl) in 0.5 µl 10X enzyme buffer (New England Biolabs) supplemented with 0.5 BSA
(100μg/ml) and 16 μl ultrapure water. The reaction was allowed to incubate for one hour.
Reaction product was subjected to gel electrophoresis to visualize resultant bands
conferring proper insert orientation.

Clones that contained the correct insert orientation

presented bands similar in size at 5563 bp and 4145 bp (Figure 3).

Products were

confirmed by gel electrophoresis in five of thirteen samples. These plasmids were selected
for site directed mutagenesis and sequencing.
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12,216 bp

3,054 bp
2,036 bp
1,636 bp
1,018 bp

Colony #: 1

2
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13

Figure 3.
XMN-1 Digestion of hVMAT1-pCMV6-Neo to Determine Insert
Orientation. Human VMAT1 insert was removed from the original vector with the Not-1
restriction enzyme. The insert was then ligated into the pCMV6-Neo vector with the T4
ligase.. Orientation of the insert was determined by digestion of the plasmid with XMN-1
restriction enzyme. Correct orientation yielded bands of 5563 bp and 4145 bp, whereas,
incorrect orientation of the insert yielded bands of 7383 and 2325 bp when analyzed by gel
electrophoresis.

Site Directed Mutagenesis of hVMAT1 in Neomycin Vector
In order to create the nucleotide polymorphism of interest, site directed
mutagenesis was performed with the QuickChange II XL Site Directed Mutagenesis Kit
( #200521, Stratagene La Jolla, CA) according to manufacturer’s protocol. Primers for
mutagenesis were determined with the QuickChange Primer Design Program
(http://www.stratagene.com/sdmdesigner/default.aspx) and purchased from (Invitrogen).
Primers spanned the target area and are represented in Table 2.
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Table 2. Mutagenesis and Sequencing Primers
Primer Target
Mutagenesis
C277A

Sequencing
Primers

Forward Primer 5'-3'

Reverse Primer 5'-3'

GGCCATCACCATGCTCCGGACCATTCTG
GGACTTTCCAAAATGTCG
CCTGACCTCCCTGTGTGTTCC
CCCTTACATCCTGGTGGCTGC

CCGGTAGTGGTACGAGGCCTGGTAAG
ATTAGGACAAGGCTGGTGGG
GGCCGGACTGGGGCAGTCTTCCC
CAGACGAAGGAAACTCAC

GGTGGCTGTGTTCCCTAATC
GCCCTCGCCTCTCCTGCC
CGGAAGAGTGTTACCC
GGCCCGAACCCTTCAAGGC

CCCCAAGGCCAGGCCCC
CCTCCCCCAGAGGAAATTCC
GAGGGTACACTCTTTCCG
CCTCCCCCAGAGGAAATTCC

Cells
The COS-1 kidney fibroblast cell line was obtained from American Type Culture
Collection (ATCC # 30-2002, Manassas, VA). Cells were maintained at 37° C with 5%
CO2 in DMEM medium (# 30-2002, ATCC) containing 4 mM L-glutamine, 4.5 g/L
glucose and 1.5g/L sodium bicarbonate. COS-1 medium is supplemented with 10% heat
inactivated fetal bovine serum, 100 units/ml penicillin and 100 units/ml streptomycin.
CHO K1 cells were obtained from Dr. Bruno Steiger, Geneva Switzerland and
maintained at 37° C with 5% CO2 in DMEM medium (#11885-092, Invitrogen) containing
4mM L-glutamine, 5mM glucose and 0.4 mM glycine. Medium was supplemented with
10% heat inactivated fetal bovine serum, 50 μg/ml L-proline, 100 units/ml penicillin and
100 units/ml streptomycin. Because CHO cells were transfected with plasmids containing
a gene that confers neomycin resistance, these cells were maintained in a medium
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supplemented with 500 μg/ml Geneticin (# 10131-035, Invitrogen). As the cells grow and
divide, the medium selects against cells that do not have the plasmid.

Cell Transfection
Cells were transfected with VMAT-1 cDNA or vector alone by electroporation as
described by Finn et. al. COS-1 cells were grown to confluency in T-75 flasks and fed
fresh medium 24 hours prior to electroporation. The day of electroporation, cells were
rinsed with calcium-and magnesium-free phosphate buffered saline (PBS), detached with
0.25% trypsin and medium containing serum added to inactivate trypsin. Cells were
pelleted by centrifugation (500 x g for 5 min at 4 C). COS 1 cells were resuspended in 700
μl of warm PBS containing calcium and magnesium (Invitrogen), whereas CHO cells were
resuspended in ice-cold PBS containing calcium and magnesium (Invitrogen) and
remained on ice for 10 min prior to electroporation. The cell suspension and 15 μg of DNA
was transferred to a 0.4 cm gap cuvette in the Gene Pulser II (Bio-Rad, Hercules, CA).
Suspension and DNA were electroporated at 0.4 kV and 950 μF. CHO cells were placed on
ice for 10 min prior to replating. Cells were replated in a T-75 flask containing fresh
medium and incubated prior to membrane preparation for transport assays.

Membrane Preparation
The third day after electroporation, cells were rinsed with PBS. After removal of
PBS, lysis buffer (containing 0.32 M sucrose, 10 mM Hepes adjusted to pH 7.4 with 1M
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KOH) supplemented with proteolytic inhibitors as described by Finn et. al (7), was added
to the T-75 flask. Cells were then scraped with a cell scraper into the lysis buffer. The cell
suspension was pelleted (500 x g for 5 min) and the supernatant removed. Cells were then
resuspended in 100 μl lysis buffer. The cell suspension was homogenized 40 strokes with a
Dounce homogenizer, and homogenate was pelleted at 3500 x g for 10 min at 5 ° C. The
supernatant was taken and aliquoted, and the pellets were resuspended in 150 µl of SH
buffer with proteolytic inhibitors and aliquoted. Total protein for the supernatant was
measured with the Bio-Rad protein assay (Bio-Rad, Hercules, CA). Aliquots were stored at
-70 ° C until assayed for VMAT-1 activity.

Western Blotting
CHO-K1 and COS-1 cells membranes were prepared as described above. With the
help of Dr. Krista Stenger (University of Richmond, Richmond, VA), proteins were
separated by electrophoresis on 10% polyacrylamide gels and transferred to nitrocellulose.
Blots were incubated overnight at 4 ° C or for 1 hour at room temperature in blocking
solution containing Tris buffered saline, 0.1% Tween-20 (TBST) and 5% dry milk, and
subsequently incubated overnight at 4 ° C with a primary goat polyclonal anti-VMAT-1
antibody (C-19; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, sc-7718) diluted 1:200 in
TBST. This antibody targets the COOH-terminal end of human VMAT1. Blots were
washed with TBST and incubated with a 1:7500 dilution of bovine anti-goat
IgG-horseradish peroxidase (HRP) (Santa Cruz Biotechnology Inc., sc-2378) for 1 hour at
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room temperature. The blots were visualized with enhanced chemiluminesence
(Amersham, Biosciences, UK). Blots were stripped using Re-Blot Plus Mild for 15 min,
blocked 2X for 5 min with blocking solution and probed again with a mouse monoclonal
anti-actin antibody (clone AC-15; Sigma) diluted 1:5000 in TBST for 1 hour at room
temperature. Blots were washed with TBST and incubated with a 1:7500 dilution of goat
anti-mouse IgG-horseradish peroxidase (HRP) (Santa Cruz Biotechnology Inc., sc-2031)
for 1 hour at room temperature and visualized as described above.
A blocking peptide was used to neutralize the reactivity with AB #1: A five-fold
excess of peptide was incubated with the appropriate dilution of antibody in 500 μl of
TBST overnight at 4 º C with agitation. Following neutralization the antibody/peptide
mixture was added to the appropriate final working volume of TBST as a substitute for the
primary antibody alone, and the western blot procedure was performed as usual.

VMAT Uptake Assay
Each assay contained 30 μg of cell protein, 5 mM ATP and 20 nM 3H labeled
serotonin [3H-5HT] (Amersham Biosciences, Piscataway, NJ) in a final volume of 200 μl
uptake buffer. Tubes were then incubated at 29 ° C for 10 min, except in preliminary time
course experiments. The reaction was terminated with 1.5 ml cold SH buffer and filtered
rapidly through 0.2 μm Supor 200 membrane filters (Pall/Gellman #60300) in a Millipore
sampling manifold. The reaction tubes were rinsed with an additional 1.5 ml cold SH
buffer and dispensed to the proper filter. Filters were transferred to a scintillation vial
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containing 5 ml of ScintiSafe scintillation fluid (Fisher Scientific, Atlanta, GA) and
reactivity determined with a Beckman LS6000IC scintillation counter.

The reaction

kinetics were analyzed with Prism software (GraphPad Prism, La Jolla, CA).

Statistics
Statistical analysis was performed using the GraphPad Prizm4 program ( GraphPad
Software Inc La Jolla, CA).

Results

Site Directed Mutagenesis of hVMAT1-pCMV6-Neo
A BLAST alignment with a GenBank reference sequence for human VMAT-1
(GenBank # NM_003053.1) revealed that the Origene human VMAT1 sequence contained
the A277C SNP of interest. The SNP results a cytosine (c) to adenine (a) change resulting
in a threonine rather than a proline at residue 4 of the protein. To determine if this finding
was correct, a sample of the Origene human VMAT1 was sequenced by the Sequencing
Core at VCU (Figure 4A). Indeed, the A277C SNP was found to be present in the human
DNA provided by Origene (Rockville, MD SC122643). Site directed mutagenesis to
revert the C to A, and the mutagenesis was verified to be successful and reflected wild type
human VMAT1 (VMAT, Figure 4B). Both VMAT1 and A277C were fully sequenced
(Figures 5 and 6).
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Creation of Stably Transfected Cell Lines
Western blot analysis confirmed the presence of hVMAT1 protein in transfected
cell extracts (Figures 7 and 8). Three immunoreactive bands at 55, 58 and 72 kDa
respectively were detected in the pellet fraction of CHO wild type cells. This indicates the
presence of cross-reactivity of hamster VMAT1 with the antibody targeting the human
VMAT1 C-terminus. In cells transfected with human VMAT1 carrying the A277C
mutation, the 55 kDa band was either absent (Figure 7) or reduced in the protein pellet
fraction (Figure 8). The 58 kDa band was more evident, however, in cells with the A277C
mutation than in non-transfected wild type cells, suggesting the transfection was
successful. Cells transfected with human VMAT1 matching the reference sequence
(GenBank: #NM_003053.1; indicated as VMAT in Figures 7 and 8) exhibited overexpression of the 58 kDa band and slightly increased expression of the 55 kDa band over
that observed in wild type CHO cells.
Results of densitometric analysis of the the 55 and 58 kDa bands are shown in
Figure 9 . A277C pellet produced a 58 kDa band 0.5 times the density of itsrespective
actin band. A277C pellet did not produce a measurable 55 kDa band. VMAT1 protein
pellet produced bands at 55 kDa and 58 kDa, which showed a density of 1.6 and 0.8 times
their respective actin bands. VMAT1 supernatant produced one band at 58 kDa which
measured 0.8 times the density of the actin band. WT CHO supernatant did not produce
measurable band at 55 or 58 kDa. WT pellet however, produced bands at 55 and 58 kDa.
These bands measured 0.36 and 0.3 times the respective actin bands.
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Analysis of Serotoin Binding Activity

Assay of serotonin binding activity of protein from permanently transfected and
wild-type CHO cells or transiently transfected and wild type COS1 cells was analyzed by
radioactive ligand binding assay. Binding activity of either supernatant or pellet protein
fractions from transfected CHO and COS1 cells showed no statistical difference in activity
when compared to protein from wild-type cells (Figures 10 and 11).

Discussion
.
The A277C mutation has been linked to schizophrenia in more than one nationality
by several laboratories. The effect of this mutation on the function and expression of
VMAT1 is unknown. This study was one of the first to investigate the effect of SNPs in
the human VMAT1 gene on cellular expression of the VMAT1 protein. DNA was obtained
from a manufacturer and found to contain the A277C SNP of interest. Site directed
mutagenesis was successfully performed, resulting in a sequence matching the reference
sequence (GenBank: #NM_003053.1) for use in stable transfections.
Transfection of human VMAT1 into CHO cells was successful as determined by
Western blot analysis. Western blotting also revealed several points of interest. In cells
20

with the A277C SNP, immunoreactive VMAT1 proteins (58 and 72 kDa) were detected,
but expression of the expected protein band at 55 kDa was either reduced or absent. This
does not appear to be due to failure of the antibody to bind to the mutated region of the
sequence, as the A277C mutation is near the NH2 terminus of the protein, and the antibody
targets the COOH terminus. Alternatively, lack of the 55 KDa VMAT1 may reflect other
effects on VMAT1 processing that made the protein more vulnerable to degradation. This
hypothesis can be explored by immunoprecipitation and subsequent western analysis for
ubiquitinated VMAT1.
Binding assays revealed no difference in activity between any cell treatment: WT,
A277C or VMAT1. Both pellet and supernatant were tested for the activity of VMAT1.
Wild type cells showed relatively high binding of tritiated serotonin. The Western analysis
revealed the presence of imunnoreactive hamster VMAT1 in the pellet fraction of wildtype cells, accounting for the high binding. However, use of positive controls did not yield
results observed in the past. This confirms that the assay procedure may need to be revised.
Also, we cannot exclude the possibility that wild type or mutated human VMAT1 that is
expressed in CHO cells may have very little activity. This hypothesis cannot be confirmed
without further study.
This study has provided a preliminary base for performing future experiments.
Additional transport assays would provide great insight into the effects of mutation on
activity of human VMAT1. Despite extensive troubleshooting of the transport assay,
measurable VMAT1 activity was not seen. The assay protocol may have to be revised. A
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different transport assay utilizing intact cells may provide a better measure of VMAT1
activity in transfected cells.
Further Western blot analysis utilizing various molecular weight ladders and
antibodies are required to obtain a clearer picture of the expression of VMAT1 within
transfected cells. The amount of ubiquitinated VMAT1 within A277C samples could be
tested in order to determine whether the A277C VMAT1 is in fact degraded quickly after
formation. In order to achieve this goal, proteasome activity in cells would have to be
inhibited.
This study provides the first evidence of the affect of the A277C SNP on the
formation of the VMAT1 protein in mammalian cells. Stably transfected cell lines
containing either VMAT1 or A277C have been successfully created. It was determined
that the A277C SNP results in a protein change of VMAT1 eliminating the 55 kDa product
as determined by western blot analysis. This novel study provides a great base for future
study of the A277C mutation.
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Figures

A
A277C
hVMAT1

ATCACCATGCTCCGGCCCATTCTGGATGCTCCCCAGCGGTTGCTGAAGGAGGGGAGAGCG
||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
ATCACCATGCTCCGGACCATTCTGGATGCTCCCCAGCGGTTGCTGAAGGAGGGGAGAGCG

570

ATCACCATGCTCCGGACCATTCTGGATGCTCCCCAGCGGTTGCTGAAGGAGGGGAGAGCG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATCACCATGCTCCGGACCATTCTGGATGCTCCCCAGCGGTTGCTGAAGGAGGGGAGAGCG

563

321

B
VMAT
hVMAT1

321

Figure 4. Site Directed Mutagenesis of VMAT 1 sequences. (A) Sequencing of the
VMAT1 DNA provided by Origene (Rockville, MD) indicated the presence of SNP
A277C highlighted in pink. The sequence is aligned with the hVMAT1 reference
sequence (GenBank NM_003053.1) (B) The Origene DNA was subjected to site directed
mutagenesis, which reverse-mutated A277C to a VMAT sequence matching the hVMAT1
reference sequence(GenBank: # NM_003053.1) as highlighted in yellow.
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92
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201
1261
1321
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1621
1681
1741
1801
1861
1921
1981
2041
2101
2161
2221
2281
2341
2401
2461
2521
2581
2641
2701

gctaacagct
cctcacacca
tccataaagg
aaagactgcc
ttgctgaagg
ctcctggaca
atggagttca
gccctcgcct
gttgaagaaa
cctccagcca
ttggaggaag
ctggtcaacc
gctggctttg
ctactctttg
cttggaatgc
gctctggggg
gagtttgttg
gcactccagc
cccctcttta
gccaacatgg
tgctccccca
ggcaccaacc
gggatgctgg
ctcattggcc
cccatcatgg
atcgctgatg
gtaaaggcca
gctccactct
agtcaggact
cctctggggg
cttgaattca
gcccacggct
tggacactgt
ggtgccgcag
aggttgatta
gtagtgagta
cctgattttc
gtgttctttc
ccaaatgcca
aaagtgagtg
aaaagtgtct
gttattgaca
cttagaaata
ggaagaagtt
gggtgtaatg

gccaatacct
acatgggctc
ctgcaggaga
ccagtccggc
aggggagagc
acatgctgtt
aagaagtcaa
ctcctgcctt
gcgtacctag
ctgaagccat
agattacccg
cattcgtggg
ttatcatgtt
tggcccgaac
tggccagtgt
gcctggcctt
ggaagtctgc
tttgcatcct
tgcttctcaa
gggtggccat
agtggcagct
tctttggtgt
tagtaggtac
ccaatgcagg
ggcacctggt
tggctttttg
tcggttttcc
gctactacct
gccccatgga
aggacagtga
tgatgcctca
cagtgggctt
ccctgatact
tggcccatct
aacttgagct
atgtgcccct
tctggcatag
ccgggttttc
gcttgaagag
atttttctgt
tctattttca
ttctcctgac
aaagtagaag
aaaagaaact
tgacattgtt

cactgagtg
caagtgagtt
cctgtagctg
catcaccatg
gtcccggcag
tactgtggtg
ctcttctctg
ttccaccatc
tggaatagca
ctcagctcat
ggtcggggtt
ccctctcacc
tctctccaca
ccttcaaggc
ctacactgat
ggggttgctg
acccttcctc
acagccttcc
agacccttac
cctggagccc
gggtctagct
gttggccaac
cagcttgctc
gcttggcctt
ggatctacgc
catgggcttt
ctggctcatg
gcggagcccc
gacccggatg
tgaggagcct
gtgaccacct
cacatacctc
cttctcacct
tttatgggaa
gtgacgggtt
gaaaccagtg
tcccaacaga
ccagccgagt
ttttgttttg
ggctaaatct
ttatctttca
ctcccctgtg
aaagacagaa
gccttgaaat
catacttgct

tccttcgtct
tcacaggacc
ctccggccca
ctggtgctgg
gtgccaattg
cacctcggcc
ttctccttct
tggatgaatg
aaaaacaact
ctgtttgctt
aacaggattg
gttatgtttg
attggatctt
gaccatgaga
gtgggagctc
atcctggcct
aaagtctctc
atcctggtgg
acactgccca
ttcttgcctg
aagatgggtc
tgtgttcctc
gccataggca
cacacctcgg
gctataggtc
gtcatcactg
ccggcaaagg
tatgcaaccc
gaccatgagg
ctttccctgg
tgcctgggaa
gtgtaacttg
gacagagtga
ctgcaagggg
gggtgactga
tcggaagagt
tgagaaaatg
ttttttttcc
agagctgcta
gaaacaggag
tgttcctacc
aaaataactg
ccctcctgat
aataaataca

gggcagactc
ttccctaaga
ttctggatgc
tggtggtatt
tgcccacctt
atgccggaag
tcaacaacaa
acactgccag
gcttgcaagg
caaaggctgt
gatatcatat
ctttttctgg
cattttcatc
gaggacgagc
cctttggaag
tcctggcact
ctgagagtgc
ctgcagggtc
tctggatgat
ccagtgtgtc
ggtggctgtg
tggctcacaa
tggtggattc
tgtatgggag
catccaccgg
gggtcatcaa
aagagaagct
agaagcccac
agtagcagca
gaccagatca
tcttctttcc
tagctcttcc
tgcaccttcc
tgactcattg
caagcctctt
gttaccctct
ttctcagcat
atttattttt
aaagggcttt
cccatttctc
ttttctgaac
attagaccca
tgtagatttc
ttattgcct

cctcccctct
gcccgcaggg
tccccagcgg
cgtcgctttg
cctatatgac
ttccccacat
caccgtggct
caccatccca
cacaggtttc
gatgcaactt
ccccatgttt
gacctatact
tgttgcaggt
catgggaact
tgtaatgtac
actggatgga
caaggggact
catctgcttt
gcagaccatg
ctacctcatt
ttccctaatc
tatttttggt
ttctatgatg
tgtctacgcc
tggtgccatt
catcgtctat
tgctattctg
gaaggaattt
gaaggtgctc
ccatggctga
tcccctccca
tctatgcctt
cgctgctgtg
catagaggtg
taatctgttg
tttcctcaac
tgtcttgctg
tttttttaat
accctcagtg
ttctgctgga
ctcttagact
agatttcatg
ctaataggag

Figure 5. Sequence of hVMAT1 DNA Obtained from Origene (A277C). After
obtaining the plasmid, it was sent to the sequencing core (VCU). It was determined that the
plasmid contained the SNP of interest and the remainder of the sequence was identical to
human VMAT1 (Gen Bank: #NM_003053.1). Start and stop codons are highlighted.
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gctaacagct
cctcacacca
tccataaagg
aaagactgcc
ttgctgaagg
ctcctggaca
atggagttca
gccctcgcct
gttgaagaaa
cctccagcca
ttggaggaag
ctggtcaacc
gctggctttg
ctactctttg
cttggaatgc
gctctggggg
gagtttgttg
gcactccagc
cccctcttta
gccaacatgg
tgctccccca
ggcaccaacc
gggatgctgg
ctcattggcc
cccatcatgg
atcgctgatg
gtaaaggcca
gctccactct
agtcaggact
cctctggggg
cttgaattca
gcccacggct
tggacactgt
ggtgccgcag
aggttgatta
gtagtgagta
cctgattttc
gtgttctttc
ccaaatgcca
aaagtgagtg
aaaagtgtct
gttattgaca
cttagaaata
ggaagaagtt
gggtgtaatg

gccaatacct
acatgggctc
ctgcaggaga
ccagtccggc
aggggagagc
acatgctgtt
aagaagtcaa
ctcctgcctt
gcgtacctag
ctgaagccat
agattacccg
cattcgtggg
ttatcatgtt
tggcccgaac
tggccagtgt
gcctggcctt
ggaagtctgc
tttgcatcct
tgcttctcaa
gggtggccat
agtggcagct
tctttggtgt
tagtaggtac
ccaatgcagg
ggcacctggt
tggctttttg
tcggttttcc
gctactacct
gccccatgga
aggacagtga
tgatgcctca
cagtgggctt
ccctgatact
tggcccatct
aacttgagct
atgtgcccct
tctggcatag
ccgggttttc
gcttgaagag
atttttctgt
tctattttca
ttctcctgac
aaagtagaag
aaaagaaact
tgacattgtt

cactgagtg
caagtgagtt
cctgtagctg
catcaccatg
gtcccggcag
tactgtggtg
ctcttctctg
ttccaccatc
tggaatagca
ctcagctcat
ggtcggggtt
ccctctcacc
tctctccaca
ccttcaaggc
ctacactgat
ggggttgctg
acccttcctc
acagccttcc
agacccttac
cctggagccc
gggtctagct
gttggccaac
cagcttgctc
gcttggcctt
ggatctacgc
catgggcttt
ctggctcatg
gcggagcccc
gacccggatg
tgaggagcct
gtgaccacct
cacatacctc
cttctcacct
tttatgggaa
gtgacgggtt
gaaaccagtg
tcccaacaga
ccagccgagt
ttttgttttg
ggctaaatct
ttatctttca
ctcccctgtg
aaagacagaa
gccttgaaat
catacttgct

tccttcgtct
tcacaggacc
ctccggacca
ctggtgctgg
gtgccaattg
cacctcggcc
ttctccttct
tggatgaatg
aaaaacaact
ctgtttgctt
aacaggattg
gttatgtttg
attggatctt
gaccatgaga
gtgggagctc
atcctggcct
aaagtctctc
atcctggtgg
acactgccca
ttcttgcctg
aagatgggtc
tgtgttcctc
gccataggca
cacacctcgg
gctataggtc
gtcatcactg
ccggcaaagg
tatgcaaccc
gaccatgagg
ctttccctgg
tgcctgggaa
gtgtaacttg
gacagagtga
ctgcaagggg
gggtgactga
tcggaagagt
tgagaaaatg
ttttttttcc
agagctgcta
gaaacaggag
tgttcctacc
aaaataactg
ccctcctgat
aataaataca

gggcagactc
ttccctaaga
ttctggatgc
tggtggtatt
tgcccacctt
atgccggaag
tcaacaacaa
acactgccag
gcttgcaagg
caaaggctgt
gatatcatat
ctttttctgg
cattttcatc
gaggacgagc
cctttggaag
tcctggcact
ctgagagtgc
ctgcagggtc
tctggatgat
ccagtgtgtc
ggtggctgtg
tggctcacaa
tggtggattc
tgtatgggag
catccaccgg
gggtcatcaa
aagagaagct
agaagcccac
agtagcagca
gaccagatca
tcttctttcc
tagctcttcc
tgcaccttcc
tgactcattg
caagcctctt
gttaccctct
ttctcagcat
atttattttt
aaagggcttt
cccatttctc
ttttctgaac
attagaccca
tgtagatttc
ttattgcct

cctcccctct
gcccgcaggg
tccccagcgg
cgtcgctttg
cctatatgac
ttccccacat
caccgtggct
caccatccca
cacaggtttc
gatgcaactt
ccccatgttt
gacctatact
tgttgcaggt
catgggaact
tgtaatgtac
actggatgga
caaggggact
catctgcttt
gcagaccatg
ctacctcatt
ttccctaatc
tatttttggt
ttctatgatg
tgtctacgcc
tggtgccatt
catcgtctat
tgctattctg
gaaggaattt
gaaggtgctc
ccatggctga
tcccctccca
tctatgcctt
cgctgctgtg
catagaggtg
taatctgttg
tttcctcaac
tgtcttgctg
tttttttaat
accctcagtg
ttctgctgga
ctcttagact
agatttcatg
ctaataggag

Figure 6. Sequence of hVMAT1 DNA Subject to Site Directed Mutagenesis (VMAT).
After site directed mutagenesis, the plasmid was sent to the sequencing core (VCU). It was
determined that he plasmid was mutated successfully to match the reference sequence and
the remainder of the sequence was identical human VMAT1 (GenBank: #NM_003053.1).
Start and stop codons are highlighted.
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VMAT1

85 kDaa

40 kDaa

A277C
S1

A277C
P1

VMAT1 VMAT1
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WT
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WT
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β-Actin

40 kDa

A277C
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A277C
P1

VMAT1
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VMAT1
P1

WT
S1

WT
P1

Figure 7. Expression of VMAT1 Protein in CHO-K1 Transfected Cells. Stably
tranfected CHO-K1 cell lines containing either the A277C mutation (Origene sequence) or
the reference VMAT1 sequence created with site-directed mutagenesis. S1 denotes cell
lysate supernatant, and P1 denotes the 3500 x G cell lysate pellet. WT denotes wild type
CHO cell protein (cells not transfected).

26

VMAT1

85 kDa
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A277C
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VMAT
S1

VMAT
P1

WT
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WT
P1

Figure 8. Expression of VMAT1 Protein in CHO-K1 Transfected Cells. (S1 =
supernatant and P1 =pellet) Stably tranfected CHO-K1 cell lines expressed either the
A277C mutation (Origene sequence) or the wild type VMAT1 sequence created with sitedirected mutagenesis. S1 denotes cell lysate supernatant. P1 denotes cell lysate pellet. WT
denoted wild type CHO protein. The above blot utilized cell protein from a separate
harvest from protein in Figure 7.
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WT P1

CHO Transfection (58 kDa Band)
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Figure 9. Expression of hVMAT1 in Transfected Cells. CHO cells were transfected
with either the A277C or VMAT1 plasmids and harvested when confluent. Cell lysate
supernatant and pellet were subject to western blot analysis by Dr. Krista Stenger
(University of Richmond). Density of resultant bands were measured with ImageJ (NIH)
and compared to their respective β-actin bands.
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Figure 10. Binding of Serotonin to Transfected hVMAT1 Protein. CHO-K1 cells
were stably transfected with either the A277C or VMAT1 plasmids. Cell lysate pellet (P1)
protein was incubated for 10 min in the presence of 5mM ATP and 20 nM tritiated
serotonin.
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Figure 11. Serotonin binding activity in transiently transfected COS-1 Cells. COS1
cells were transiently transfected with either the A277C or VMAT1 plasmids. Cell lysate
pellet and supernatant protein activities were analyzed by radioactive ligand binding assay.
Cell supernatant and pellet demonstrated significant differences in activity despite cell
treatment (* p > 0.05 compared to all S1 fractions). No significant differences were
observed in activity among wt and transfected cells.
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